Pain Management Market Estimated to Grow Substantially at a 6% CAGR between 2018 to 2023
Pain is a complex medical issue usually caused by and creates physical and mental discomfort to the patient. Pain management is one of the most common medical condition treated by medical professionals, occurring due to tissue damage, or disease. Necessary treatment depends on the intensity of the pain, which varies from person to person and may require either simple or complicated treatment procedures such as pharmacological therapy or non-pharmacological therapy such as medical devices.
The market growth of the global Pain Management Market is estimated to rise primarily due to the ever-increasing dependency of patients on painkiller medication. According to Market Research Future (MRFR), the growing investment in creating non-opioid medication to reduce addiction to opioid drugs is assessed as a factor influencing the market significantly over the forecast period of 2018 to 2023 and the market is estimated to rise at a 6% CAGR.
Also Read http://www.digitaljournal.com/pr/4315184
Pain Management Market Key Players
Key players identified in the global pain management market are Abbott Laboratories, Abbvie, Allergan, Astellas Pharma, AstraZeneca plc, Bayer AG, Codman And Shurtleff, Inc., DJO Global LLC, Eli Lilly & Company, Endo Health Solutions, F. Hoffmann-La Roche Ltd, Forest Laboratories, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Mallinckrodt plc, Medtronic PLC, ST. Jude Medical, Inc., Boston Scientific Corporation, Pfizer Inc., Halyard Health, Inc., Smiths Medical, B. Braun Melsungen AG, Neurotech Na, Inc., Becton, Dickinson and Company, Nevro Corp., Merck & Co. Inc., Novartis AG, Purdue Pharma LP, Sanofi, Stryker Corporation, Teva Pharmaceuticals, and others.
Intended Audience
- Pharmaceutical Companies
- Medical Devices Companies
- Research and Development (R&D) Companies
- Government Research Institutes
- Academic Institutes and Universities
Pain Management Market Segmental Analysis
The global pain management market has been segmented based on the type of pain management device, type of pain management drug, indication, mode of purchase, end-user, and region.
Based on the type of pain management device, the market is segmented into the neurostimulation device, analgesic infusion pump, an ablation device. The neurostimulation device segment is segmented into Transcutaneous Electrical Nerve Stimulation (TENS) devices and Spinal Cord Stimulation (SCS) devices. Ablation devices are segmented into RF ablation devices and cryoablation devices.
Based on the type of pain management drug, the market has been segmented as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), anticonvulsants, anesthetics, opioids, antimigraine agents, antidepressants, and others. The opioids section is segmented as oxycodone, hydrocodone, tramadol, morphine, codeine, fentanyl, meperidine, methadone, and others.
Based on indication, the pain management market has been segmented into, neuropathic pain, cancer pain, facial pain and migraine, musculoskeletal pain, fibromyalgia, chronic back pain, arthritic pain, migraine, post-operative pain, others. The musculoskeletal pain segment is estimated to hold the largest market share while the cancer pain segment is assessed to witness the highest growth rate over the forecast period influenced by the rising number of cancer patients, and the treatment methods, such as the drugs, and procedures are estimated to contribute to the market share.
Based on the mode of purchase, the market is segmented into over-the-counter and prescription-based.
Based on the end-user, the market is segmented into hospitals and clinics, pharmaceutical companies, medical device companies, research and academic institutes, and others.
Based on regions, the global pain management market has been segmented into North & South America, Europe, Asia Pacific, and Middle East & Africa.
Pain Management Market Regional Analysis
North & South American regional market is leading the market share of the global pain management market and is estimated to sustain its dominant market position over the forecast period, owing to the growing prevalence of chronic pain and illness, technologically advanced medical devices, significant healthcare expenditure, and the presence of leading global market players and pain specialist doctors. The most frequently diagnosed medical conditions are low back pain, and headaches.
Europe is assessed as the second largest regional market for pain management and is estimated to rise significantly over the forecast period influenced by factors such as the increasing investments towards research and development of pain management devices and drugs.
Asia Pacific region is estimated to rise as the fastest growing pain management regional market due to its high number of patients, which increases the demand for treatment and has created a rise in the healthcare expenditure.
The Middle East and Africa hold a comparatively lower market share of the global pain management market due to the low rate of development, lack of medical knowledge, professionals and facilities.
Table Of Contents:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Pain Management Market, By Type Of Pain Management Devices
6.1 Introduction
6.2 Neurostimulation Devices
6.2.1 Market Estimates & Forecast, 2018–2023
…To be Continued.
Browse Complete Premium research Report Enabled with TOC@ https://www.marketresearchfuture.com/reports/pain-management-market-5975
This is likely to remain a threat in the Pain Management Market over the forecast period, as the increasing financial implications of the healthcare sector have raised the stakes for players operating in the industry.
The global Drug Discovery Informatics market size is expected to reach USD 12.52 billion by 2028 according to a new study by Polaris Market Research.
The report “Drug Discovery Informatics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Antibacterial Drugs {Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, Others}, Antiviral Drugs, Antifungal Drugs); By Infection Type; By Regions; Segment Forecast, 2021 – 2028” gives a detailed insight into current market dynamics and provides analysis on future market growth.Rising tolerance towards antibiotics in lethal pathogens also induced the market demand for novel therapeutics for treating hospital acquired infections.
The majority of players in the market for Drug Discovery Informatics are continuously involved in research & development activities to develop new drugs to gain a competitive advantage.In this direction, in June 2019, Food & Drug Administration (FDA) approved Merck’s Zerbaxa (ceftolozane and tazobactam) drug for the treatment of ventilator-associated infections in patients aged 18 years and older.
This is expected to drive the market for Drug Discovery Informatics.Over the past few decades, chronic diseases such as diabetes, heart-related ailments, and arthritis are rising at an alarming speed.
As per the data published by International Agency for Research on Cancer (IARC), in 2018, reported around 18.1 million new cancer cases.Get Sample PDF @ https://www.polarismarketresearch.com/industry-analysis/drug-discovery-informatics-market/request-for-sampleAsia Pacific is expected to register a lucrative market growth rate over the hospital acquired infection therapeutic study period.
This market growth for hospital acquired infection therapeutic is attributed to the rising prevalence of chronic diseases in developing nations with high disposable income, which had led to an increase in hospital admissions.For instance, as per the market study done by Globocan, in 2018, there were 4,285,033 new cancer cases in China.
Market HighlightsTruncus arteriosus is a rare congenital cardiovascular disease.
Increasing prevalence of cardiovascular diseases, adoption of advanced techniques in diagnosis, and increasing government support is driving the growth of the market.
Increasing prevalence of diabetes, rapidly developing technology, across the globe is further fuelling the growth of the market.
However, higher cost of the treatment methods may slow the growth of the market over the assessment period.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/5260Regional AnalysisThe Americas command a major share of the market owing to the huge patient population suffering from cardiovascular diseases & diabetes, increasing demand for the advanced devices, and strong government support.
Additionally, availability of funds is expected to fuel the growth of the market.The Middle East & Africa holds the least share of the global market due to limited availability of medical facilities and poor economic conditions in the African region.
The Middle East holds the major share in the market in this region owing to a well-developed economy, whereas, African region is expecting a healthy growth due to the presence of huge opportunity in the market.SegmentationThe global truncus arteriosus market has been segmented on the basis of types, diagnosis, treatment and end user.
Connective Tissue Disease Market Research Report information: Diagnosis (X-ray Examination, Antinuclear Antibody Test, Treatment (Non-Steroidal Anti-Inflammatory, Cortisone/Steroids, Antimalarial, Cytotoxic Drugs), End User - Global forecast till 2027Market HighlightsConnective tissue disease is a group of medical diseases.
Various connective tissue disorders feature abnormal immune system activity along with inflammation in tissues.
Connective tissue disorders involve multiple organs and organ systems such as, skin, joints, muscles, lungs, kidneys, eyes, heart, gastrointestinal tract, and blood vessels.According to a study published in Pan African Medical Journal in 2017, it is found that mixed connective tissue disorders are more frequent among Asians, and in the African population.
It is also reported that among Asian population, the condition is more prevalent in China, and Japan.
In the European region, the disorder is more prevalent in Italy, Hungary, Norway and Poland.Rising prevalence of connective tissue disease, high unmet needs of current treatment, and increase in research and development expenditure will promote the growth of connective tissue disease market.Lack of infrastructure in the middle and low income countries may hamper the growth of the market.It is estimated that connective tissue disease market is expected to grow at a CAGR 11.5% during the forecast period of 2017-2023.Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/4977Regional AnalysisThe Americas dominate the connective tissue disease market owing to the rising awareness among people, and increasing healthcare expenditure.
As per the facts suggested by the Centers for Disease Control and Prevention (CDC), it is found that out of total annual healthcare expenditure, 86% is for people with chronic health conditions in the United States.Europe holds the second position in the connective tissue disease market.
The Global Pharmacogenomics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2026 gives an evaluation of the market developments based on historical studies and comprehensive research respectively.
The market segments are also provided with an in-depth outlook of the competitive landscape and a listing of the profiled key players.The comprehensive value chain analysis of the market will assist in attaining better product differentiation, along with detailed understanding of the core competency of each activity involved.
The market attractiveness analysis provided in the report aptly measures the potential value of the market providing business strategists with the latest growth opportunities.The report classifies the market into different segments based on method, therapeutic application and application.
These segments are studied in detail incorporating the market estimates and forecasts at regional and country level.
The segment analysis is useful in understanding the growth areas and probable opportunities of the market.Final Report will cover the impact of COVID-19 on this industry.Browse the complete Global Pharmacogenomics Market Research Report – Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2026 @ https://www.decisiondatabases.com/ip/15450-pharmacogenomics-market-reportThe report also covers the complete competitive landscape of the global Pharmacogenomics market with company profiles of key players such as:Abbott Laboratories, Inc.Affymetrix, Inc.AstraZeneca plcBayer AGBristol-Myers Squibb CompanyF.
Hoffmann-La Roche Ltd.GE HealthcareGlaxoSmithKline plcJohnson & JohnsonMerck & Co., Inc.A detailed description of each has been included, with information in terms of H.Q, future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other latest industrial developments.SEGMENTATIONS IN THE REPORT:By Method:Haplotype AnalysisMultivariate TechniquesBy Therapeutic Application:CancerOncologyCardiovascularBy Applications:Drug SafetyTailor TreatmentsDrug DiscoveryBy Geography:North America (NA)Europe (EU)Asia Pacific (APAC)Rest of the World (RoW)Download Free Sample Report of Global Pharmacogenomics Market @ https://www.decisiondatabases.com/contact/download-sample-15450The Global Pharmacogenomics Market has been exhibited in detail in the following chapters –Chapter 1 Pharmacogenomics Market PrefaceChapter 2 Executive SummaryChapter 3 Pharmacogenomics Industry AnalysisChapter 4 Pharmacogenomics Market Value Chain AnalysisChapter 5 Pharmacogenomics Market Analysis By MethodChapter 6 Pharmacogenomics Market Analysis By Therapeutic ApplicationChapter 7 Pharmacogenomics Market Analysis By ApplicationsChapter 8 Pharmacogenomics Market Analysis By GeographyChapter 9 Competitive Landscape Of Pharmacogenomics CompaniesChapter 10 Company Profiles Of Pharmacogenomics IndustryPurchase the complete Global Pharmacogenomics Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-15450Other Reports by DecisionDatabases.com:Global ePharmacy Market Research Report – Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2026Global Genomics Market Research Report – Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2026Global Single Cell Genomics Market Research Report – Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2026About-Us:DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics.
The use of critical care diagnostics in emergency rooms is expected to account for a larger revenue share due to high footfall of patients in ER to seek instant medical attention, and receive basic life support in case of severe traumatic conditions.
It is a proven and acknowledged fact that the rate of survival of severely ill patents in the emergency department directly depends on the early recognition and treatment of diseases.
Request a sample of this report @ https://www.adroitmarketresearch.com/contacts/request-sample/1322 North America and Asia Pacific to spearhead the global market during the forecast periodNorth America is estimated to account for a significant market share.
Presence of well-established healthcare infrastructure, high healthcare expenditure and supportive government policies are attributed to the incumbent position of North America market.Critical care diagnostics market is experiencing opportunistic growth in Asia Pacific due to high prevalence of chronic diseases along with rising geriatric population.
Additionally, improving healthcare infrastructure and services in rural areas is anticipated to supplement the growth of Asia Pacific market.Browse the complete report @ https://www.adroitmarketresearch.com/industry-reports/critical-care-diagnostics-market Key Market PlayersAbbott LaboratoriesBayer AGBecton, Dickinson & CompanyBioMerieux SABio-Rad Laboratories, Inc.Chembio Diagnostic Systems, Inc.Danaher CorporationHoffmann-La RocheSiemens HealthineersSysmex CorporationOthersMarket Segments: Critical Care Diagnostics MarketaBy TypeFlow cytometryMicrobial and infectious diseasesRoutine and special chemistryHematology testImmunoproteinsCoagulation testBy End UserOperating roomEmergency roomIntensive care unitOthersBy RegionNorth AmericaUSCanadaEuropeGermanyFranceUKAsia PacificChinaIndiaJapanMiddle East and AfricaUAESouth AfricaCentral & South AmericaBrazilMexicoKey SourcesIndustry AssociationsCompany Annual ReportsCompany WebsitesKey Industry LeadersTechnology ConsultantsOthersKey Questions AnsweredWhat are the key growth regions and countries?What are the important types and technologies being used?How are the market players active, in terms of research and development?What are the integrations happening?What is the recent news, developments, mergers, or large value deals?Where will the industry go in the long run?Key StakeholdersComponent ProvidersTechnology Solution ProvidersRegulatory AuthoritiesResearch and Innovation OrganizationsSuppliers and DistributorsOther Channel PartnersQuality Control OrganizationsEnquire for in-depth information before buying this report @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/1322 About UsAdroit Market Research is an India-based business analytics and consulting company incorporated in 2018.
Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a market's size, key trends, participants and future outlook of an industry.
According to the latest market report published by Research Report Insights, titled ‘Global Hospital Acquired Infections Control Market’: Industry Analysis 2012-2016and Forecast2017-2025. The global hospital acquired infections control market is expected to expand at a CAGR of 4.8% during the forecast period 2017-2025.
The market is segmented based on product type, end user, and region.
On the basis of product type, market has been segmented as heat sterilization equipment (moist heat sterilization equipment and dry heat sterilization equipment), low temperature sterilization equipment, radiation sterilization equipment, and disinfection equipment (disinfector (washer disinfector and flusher disinfector), endoscopic reprocessor systems (single basin endoscopic reprocessor systems and dual basin endoscopic reprocessor systems), and disinfectants). Among these segments, disinfection equipment segment is expected to register the highest market share of 50.8% in 2025 and expand at a CAGR of 5.1% in terms of revenue between 2017 and 2025.
Report For Sample with Table of Contents@ https://www.researchreportinsights.com/report/sample/110114926/Hospital-Acquired-Infections-Control-Market
On the basis of end users, market has been segmented as hospitals, ambulatory surgical centers, medical institutions, diagnostic laboratories, and clinics. The hospital end use segment contributed the leading shares, and the trend is expected to continue over the forecast period. Hospitals end use segment hold the market share of 32.0% in 2017, and expand at a CAGR of 4.7 % in terms of revenue between 2017 and 2025. Followed by hospitals, ambulatory surgical centers end use segment holds the significant market share in terms of revenue over the forecast period.
By region, the global hospital acquired infections controlmarket has been segmented into North America, Latin America, Europe, Asia Pacific (APAC), and Middle East & Africa (MEA).Globally, in terms of revenue, North America has been anticipated to account for the highest share of 39.5% in 2017 and expand at a CAGR of 4.2% in terms of revenue between 2017 and 2025, followed by Europe. Meanwhile, revenue from the market in Asia Pacific (APAC) is expected to expand at the significant CAGR of 5.7% over the forecast period.
The global hospital acquired infections control market shows a healthy growth over the forecast period. The factor such as shifting of healthcare model towards value-based model, increasing spending on healthcare per capita & increasing industry consolidation, and growth in emerging markets coupled with pricing pressure on the manufacturers are fueling the growth of hospital acquired infections control market. Changing demographics in the emerging economies like China, India, Brazil and South Africa is expected to provide high growth opportunities for medical device manufacturers. Public and private healthcare expenditure in these countries is expected to witness high growth which in turn is expected to drive focus of the manufacturers in these markets. In addition, increasing out-of-pocket healthcare expenditure in both developing and developed economies is expected to fuel demand for advanced endoscopy surgical procedures and thus, increase use of automated endoscope reprocessors in various healthcare sectors.
Furthermore, expanding number of hospital mergers and unions are relied upon to have wild effect on the restorative medical device producers attributable to huge number of doctor's facility arrange working under one association, these systems can influence the cost of the AERs with the makers and thus diminishing their gainfulness edges. Large patient pool & rise in disposable income coupled with increase in number of hospitals in emerging economies, and development & advancements in reprocessing in developed economies are few factor are also gardening the market growth of hospital acquired infections control.
Some of the key players in the global hospital acquired infections control market includes Olympus Corporation, Medivators Inc. (Cantel Medical Corp.), Getinge Group, STERIS Plc., Belimed AG (Metall Zug), Steelco S.P.A, Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co., Advanced Sterilization Products Services Inc. (Johnson & Johnson), Abbott Laboratories, Bayer AG, Alere Inc., The 3M Company, and Cepheid Inc.
Request For Report Discount@ https://www.researchreportinsights.com/report/discount/110114926/Hospital-Acquired-Infections-Control-Market
Theglobal hospital acquired infections control marketis segmented as follows:
By Product Type
• Heat Sterilization Equipment
? Moist Heat Sterilization Equipment
? Dry Heat Sterilization Equipment
• Low Temperature Sterilization Equipment
• Radiation Sterilization Equipment
• Disinfection Equipment
• Disinfector
• Washer Disinfector
• Flusher Disinfector
• Endoscopic Reprocessor Systems
• Single Basin Endoscopic Reprocessor Systems
• Dual Basin Endoscopic Reprocessor Systems
• Disinfectants
By End User
• Hospitals
• Ambulatory Surgical Centers
• Medical Institutions
• Diagnostic Laboratories
• Clinics
By Region
• North America
• Latin America
• Europe
• Asia-Pacific
• Middle East & Africa
Report Analysis@ https://www.researchreportinsights.com/report/rd/110114926/Hospital-Acquired-Infections-Control-Market
